Herself in Every Moment: A peer conversation on the importance of individualized treatment for children with CPP

Chapter 3: Interpreting Changes During Treatment

Drs Vargas Trujillo and Klein confer how they would monitor efficacy of GnRHa therapy over time for Chloé with CPP by tracking several measures, such as bone age to chronological age ratio, height velocity, and predicted adult height. They share how to interpret results based on outcomes from a longitudinal study published in 2022.

Chapter 1 of 4

Assessing Need for Treatment of Central Precocious Puberty

Chapter 2 of 4

Initiating CPP Treatment for Girls Older than Age 7 Years

Chapter 3 of 4

Interpreting Changes During Treatment

Chapter 4 of 4

Determining Timing of Treatment Cessation

Clinical Perspectives Presented By:

<p style="marginTop: 2rem"> Karen O. Klein, MD</p> <p>Pediatric Endocrinologist,<br /> Rady Children’s Hospital - San Diego</p> <p style='padding: 0rem 0'>Clinical Professor of Pediatrics<br /> UC San Diego School of Medicine <br />San Diego, California </p>

Karen O. Klein, MD

Pediatric Endocrinologist,
Rady Children’s Hospital - San Diego

Clinical Professor of Pediatrics
UC San Diego School of Medicine
San Diego, California

<p style="marginTop: 2rem"> Marcela Vargas Trujillo, MD</p> <p>Pediatric Endocrinologist, <br />Rady Children’s Hospital - San Diego </p> <p style="padding: 0rem 0">Associate Professor of Pediatrics<br />UC San Diego School of Medicine<br />San Diego, California</p>

Marcela Vargas Trujillo, MD

Pediatric Endocrinologist,
Rady Children’s Hospital - San Diego

Associate Professor of Pediatrics
UC San Diego School of Medicine
San Diego, California

Program Objectives

<b>Review</b> a patient case regarding a girl with central precocious puberty (CPP) and discuss an individualized treatment approach guided by recent analysis of clinical trial data

Review a patient case regarding a girl with central precocious puberty (CPP) and discuss an individualized treatment approach guided by recent analysis of clinical trial data

<b>Examine</b> the multiple factors that should be considered when deciding to initiate or discontinue CPP treatment

Examine the multiple factors that should be considered when deciding to initiate or discontinue CPP treatment

<b>Discuss</b> some of the limitation of current approaches to CPP treatment initiation and cessation

Discuss some of the limitation of current approaches to CPP treatment initiation and cessation

<b>Highlight</b> the importance of discontinuing treatment at the appropriate age of onset of puberty

Highlight the importance of discontinuing treatment at the appropriate age of onset of puberty

Additional Videos About CPP

Chapter 1 of 9

Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years

Chapter 2 of 9

Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty

Chapter 3 of 9

Patient case discussion on the importance of individualized treatment decisions in girls with central precocious puberty

Chapter 4 of 9

Vargas Trujillo CPP Study Review: Overview and Baseline Characteristics

Chapter 5 of 9

Vargas Trujillo CPP Study Review: Study Results

Chapter 6 of 9

Vargas Trujillo CPP Study Review: Conclusion

Chapter 7 of 9

Individualizing Treatment Decisions in Girls With Central Precocious Puberty

Chapter 8 of 9

CPP Patient Case: When to Treat

Chapter 9 of 9

CPP Patient Case: When to Stop Treatment
Toolkit with Additional Resource on CPP

Additional Resource

"Recognizing the Signs of Central Precocious Puberty (CPP) Earlier: Journey from Patient to Referral Through Case Studies"

https://www.contemporarypediatrics.com/view/cpp

©2023 AbbVie Inc. ABBV-US-01373-MC v1 10/2023